New Therapeutic Uses Funding Information
NIH launched the New Therapeutic Uses pilot program in May 2012. By pairing researchers with a selection of industry-provided molecular compounds, the goal of this innovative program is to test ideas for new therapeutic uses, ultimately identifying promising new treatments for patients.
In June 2013, NIH awarded $12.7 million to fund two-year and three-year cooperative agreements for nine projects in areas that include alcoholism, a type of progressive lung disease and cigarette smoking cessation. The NIH Common Fund is supporting the pilot phase of this NCATS-led program. If specific milestones are met, funded researchers will conduct pre-clinical validation, clinical feasibility studies, or proof-of-concept clinical trials to test whether selected compounds are effective against a previously unexplored disease target.
On January 27, 2014, NCATS issued the following request to industry for molecular compounds to use in next round of the New Therapeutic Uses program.
These now-expired funding announcements include details on the application process, eligibility and associated timelines:
NOT-TR-12-010: Technical Assistance Webinar for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules Limited Competition RFA-TR-12-004 (UH2/UH3) and RFA-TR-12-005 (UH3)
- Discovering New Therapeutic Uses for Existing Molecules
- 2013 Project Awards
- FAQ About New Therapeutic Uses
- New Therapeutic Uses Contacts
- Request for Program Feedback
- NIH Grant Information
- Apply for NIH Grants
- NIH Guide for Funding Opportunities
- NIH Grant FAQs
- Therapeutics for Rare and Neglected Diseases
- Bridging Interventional Development Gaps
Christine Colvis, 301-451-3903
Join NCATS Listservs
Frequently Asked Questions
- About New Therapeutic Uses
- About the UH2/UH3 and UH3 Limited Competition Application (Expired 12/18/12)
- About the X02 Pre-Application PAR-12-203 (Expired 8/15/12)